ROR2 and gastric cancer: Notably, in the intestinal type of GC, the approximately four-fold difference in the median OS was noted between the patients with high expression of ROR2 versus low expression of ROR2 (high expression cohort, median OS = 26.8 months versus low expression cohort, median OS = 113.2 months).